Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

Richard W. Joseph; Jeroen Elassaiss-Schaap; Richard Kefford; Wen Jen Hwu; Jedd D. Wolchok; Anthony M. Joshua; Antoni Ribas; F. Stephen Hodi; Omid Hamid; Caroline Robert; Adil Daud; Roxana Dronca; Peter Hersey; Jeffrey S. Weber; Amita Patnaik; Dinesh P. de Alwis; Andrea Perrone; Jin Zhang; S. Peter Kang; Scot Ebbinghaus; Keaven M. Anderson; Tara C. Gangadhar

doi:10.1158/1078-0432.CCR-18-3340

Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

Richard W. Joseph
, Jeroen Elassaiss-Schaap
, Richard Kefford
, Wen Jen Hwu
, Jedd D. Wolchok
, Anthony M. Joshua
, Antoni Ribas
, F. Stephen Hodi
, Omid Hamid
, Caroline Robert
, Adil Daud
, Roxana Dronca
, Peter Hersey
, Jeffrey S. Weber
, Amita Patnaik
, Dinesh P. de Alwis
, Andrea Perrone
, Jin Zhang
, S. Peter Kang
, Scot Ebbinghaus

Keaven M. Anderson, Tara C. Gangadhar

Research output: Contribution to journal › Comment/debate › peer-review

8 Scopus citations

Abstract

In the original version of this article (1), the stated disclosure of Jedd D. Wolchok is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article.

Original language	English (US)
Pages (from-to)	6098
Number of pages	1
Journal	Clinical Cancer Research
Volume	24
Issue number	23
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-3340
State	Published - Dec 1 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-18-3340

Fingerprint

Dive into the research topics of 'Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)'. Together they form a unique fingerprint.

Cite this

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Stephen Hodi, F., Hamid, O., Robert, C., Daud, A., Dronca, R., Hersey, P., Weber, J. S., Patnaik, A., de Alwis, D. P., Perrone, A., Zhang, J., Peter Kang, S., ... Gangadhar, T. C. (2018). Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386). Clinical Cancer Research, 24(23), 6098. https://doi.org/10.1158/1078-0432.CCR-18-3340

Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386). / Joseph, Richard W.; Elassaiss-Schaap, Jeroen; Kefford, Richard et al.
In: Clinical Cancer Research, Vol. 24, No. 23, 01.12.2018, p. 6098.

Research output: Contribution to journal › Comment/debate › peer-review

Joseph, RW, Elassaiss-Schaap, J, Kefford, R, Hwu, WJ, Wolchok, JD, Joshua, AM, Ribas, A, Stephen Hodi, F, Hamid, O, Robert, C, Daud, A, Dronca, R, Hersey, P, Weber, JS, Patnaik, A, de Alwis, DP, Perrone, A, Zhang, J, Peter Kang, S, Ebbinghaus, S, Anderson, KM & Gangadhar, TC 2018, 'Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)', Clinical Cancer Research, vol. 24, no. 23, pp. 6098. https://doi.org/10.1158/1078-0432.CCR-18-3340

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM et al. Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386). Clinical Cancer Research. 2018 Dec 1;24(23):6098. doi: 10.1158/1078-0432.CCR-18-3340

@article{6aa56a34b86246f9b0ee8c55ae46833e,

title = "Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960{\textendash}7)DOI: 10.1158/1078-0432.CCR-17-2386)",

abstract = "In the original version of this article (1), the stated disclosure of Jedd D. Wolchok is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article.",

author = "Joseph, \{Richard W.\} and Jeroen Elassaiss-Schaap and Richard Kefford and Hwu, \{Wen Jen\} and Wolchok, \{Jedd D.\} and Joshua, \{Anthony M.\} and Antoni Ribas and \{Stephen Hodi\}, F. and Omid Hamid and Caroline Robert and Adil Daud and Roxana Dronca and Peter Hersey and Weber, \{Jeffrey S.\} and Amita Patnaik and \{de Alwis\}, \{Dinesh P.\} and Andrea Perrone and Jin Zhang and \{Peter Kang\}, S. and Scot Ebbinghaus and Anderson, \{Keaven M.\} and Gangadhar, \{Tara C.\}",

note = "Publisher Copyright: {\textcopyright} 2018 American Association for Cancer Research.",

year = "2018",

month = dec,

day = "1",

doi = "10.1158/1078-0432.CCR-18-3340",

language = "English (US)",

volume = "24",

pages = "6098",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "23",

}

TY - JOUR

T1 - Correction

T2 - Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

AU - Joseph, Richard W.

AU - Elassaiss-Schaap, Jeroen

AU - Kefford, Richard

AU - Hwu, Wen Jen

AU - Wolchok, Jedd D.

AU - Joshua, Anthony M.

AU - Ribas, Antoni

AU - Stephen Hodi, F.

AU - Hamid, Omid

AU - Robert, Caroline

AU - Daud, Adil

AU - Dronca, Roxana

AU - Hersey, Peter

AU - Weber, Jeffrey S.

AU - Patnaik, Amita

AU - de Alwis, Dinesh P.

AU - Perrone, Andrea

AU - Zhang, Jin

AU - Peter Kang, S.

AU - Ebbinghaus, Scot

AU - Anderson, Keaven M.

AU - Gangadhar, Tara C.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - In the original version of this article (1), the stated disclosure of Jedd D. Wolchok is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article.

AB - In the original version of this article (1), the stated disclosure of Jedd D. Wolchok is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article.

UR - https://www.scopus.com/pages/publications/85057789854

UR - https://www.scopus.com/pages/publications/85057789854#tab=citedBy

U2 - 10.1158/1078-0432.CCR-18-3340

DO - 10.1158/1078-0432.CCR-18-3340

M3 - Comment/debate

C2 - 30510087

AN - SCOPUS:85057789854

SN - 1078-0432

VL - 24

SP - 6098

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 23

ER -

Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this